The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

A recent study reaffirmed the safety and effectiveness of guselkumab, in managing psoriasis and psoriatic arthritis over an extended period of 208 weeks (approximately 4 years). This ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

a psoriatic arthritis drug; and several that treat different forms of cancer. The list is a first step in negotiations and, ...

Healthcare professionals and patients share perspectives on US healthcare hurdles, highlighting the need to improve ...

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

If successful, the result could be lower Medicare Part D prices for drugs used to create a variety of conditions, such as ...

Biden's administration announced weight loss drugs Ozempic and Wegovy will be included on Medicare's list of medications subject to direct price negotiations.

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of 15 drugs selected for the second round of ...

U.S. Health and Human Services Secretary Xavier Becerra says “this is a big deal.” Drug companies oppose the program.

The Biden administration has added popular weight loss and diabetes drugs, including Ozempic and Wegovy, to Medicare’s list ...